Edesa生物技術 EDSA 深 滬
已收盤 02-06 16:00:00 美东时间
1.12
0.000
0.00%
華盛通- 最 高1.17
- 今 開1.10
- 成交量 5.31万股
- 最 低 1.06
- 昨 收 1.12
- 總市值 933.39万
- 52周最高 2.9516
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.9404
- 委 比 83.42%
- 總股本 833.38万
- 歷史最高 133.70
- 量 比 0.22
- 振 幅 9.82%
- 歷史最低 0.9404
- 每 手 1
- 風險率 0.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Edesa Biotech Q4 EPS $(0.32) Misses $(0.27) Estimate
Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.27) by 19.85 percent. This is a 10.34 percent decrease over losses of $(0.29) per share from
2025-12-13 05:23
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers MSP Recovery (NASDAQ:MSPR) stock increased by 36.4% to $0.3 during Fri...
2025-11-01 05:07
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
Edesa Biotech announced positive Phase 3 results for paridiprubart in treating ARDS, showing a 25% relative reduction in mortality risk and a 41% higher rate of clinical improvement. The drug met primary and secondary endpoints, demonstrated durable survival benefits, and was well-tolerated. It has potential for standard-of-care treatment in ARDS and chronic respiratory conditions, supported by funding from the Canadian government.
2025-10-28 11:45
Edesa Biotech and InflaRx: Breathing New Life into ARDS Treatment
Edesa Biotech (($EDSA)), Inflarx N.V. (($IFRX)) announced an update on their on...
2025-10-28 07:50
Edesa Biotech Amends Agreement with Canadian Government
Edesa Biotech ( ($EDSA) ) has issued an announcement. On September 30, 2025, Ed...
2025-10-01 04:27
Edesa Biotech Launches At-The-Market Offering Program
An announcement from Edesa Biotech ( ($EDSA) ) is now available. On September 9...
2025-09-10 05:00
Edesa Biotech Advances Vitiligo Treatment Amidst Steady Financial Performance
Edesa Biotech ( ($EDSA) ) has provided an announcement. Edesa Biotech reported ...
2025-08-09 07:02
Edesa Biotech Q3 EPS $(0.25) Beats $(0.29) Estimate
Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.29) by 13.79 percent. This is a 51.92 percent increase over losses of $(0.52) per share from the
2025-08-09 04:36
Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results
Edesa Biotech reported Q3 and Q9 2025 financial results, advancing manufacturing for its EB06 candidate in vitiligo with plans to submit IND data by end-2025. CEO Par Nijhawan highlighted EB06's favorable safety profile and potential benefits for patients with extensive vitiligo. Financially, operating expenses remained stable, with a slight decrease in R&D costs offset by increased EB06-related expenses. Net loss for Q3 and Q9 2025 was $1.7M and...
2025-08-08 20:35
美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
2025-06-28 08:37
